Please login to the form below

Not currently logged in
Email:
Password:

Lyxumia

This page shows the latest Lyxumia news and features for those working in and with pharma, biotech and healthcare.

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia. Sanofi's combination therapy Suliqua has been granted European marketing approval for the treatment of adults with type 2 diabetes. ... The dual-drug treatment combines the firm's

Latest news

More from news
Approximately 12 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Suliqua &Lyxumia/ Adlyxin for Type 2 diabetes. Purchase of. royalty rights.

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    Key among these for Sanofi is Lyxumia (lixisenatide), the company's new GLP-1 receptor agonist, which is planned for first launch in Germany following European approval and has been accepted ... With a single daily injection and only one step to

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics